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Patients with renal insufficiency may have increased serum troponins even in the absence of
clinically suspected acute myocardial ischemia. While cardiovascular disease is the most
common cause of death in patients with renal failure, we are just beginning to understand the
clinical meaning of serum troponin elevations. Serum troponin T is increased more frequently
than troponin I in patients with renal failure, leading clinicians to question its specificity for
the diagnosis of myocardial infarction. Many large-scale trials demonstrating the utility of
serum troponins in predicting adverse events and in guiding therapy and intervention in acute
coronary syndromes have excluded patients with renal failure. Despite persistent uncertainty
about the mechanism of elevated serum troponins in patients with reduced renal function,
data from smaller groups of renal failure patients have suggested that troponin elevations are
associated with added risk, including an increase in mortality. It is possible that increases in
serum troponin from baseline in patients with renal insufficiency admitted to hospital with
acute coronary syndrome may signify myocardial necrosis. Further studies are needed to
clarify this hypothesis. (J Am Coll Cardiol 2002;40:2065–71) © 2002 by the American
College of Cardiology Foundation
The interpretation of elevated serum markers of myocardial
necrosis in patients with renal insufficiency is controversial.
Traditional serum markers of myocardial necrosis such as
creatine kinase, MB-fraction of creatine kinase (CK-MB)
and myoglobin are commonly increased in renal failure,
even in the absence of clinically suspected myocardial
ischemia (1,2). Cardiac troponins are more specific markers
of myocardial necrosis. However, cardiac troponins are
elevated in some patients with renal failure, even in the
absence of clinically suspected ischemia (3–6). Large-scale
trials of patients with acute coronary syndromes have
documented the importance of troponin elevations in risk
stratification, prognosis, and therapeutic utilization (7–9).
However, most of these studies excluded patients with
elevated serum creatinine.
Cardiovascular disease accounts for roughly 50% of
deaths in patients with chronic renal failure (10) and in this
cohort the prevalence of coronary artery disease may be as
high as 73% (11). Patients with renal failure are at higher
risk for silent ischemia and atypical clinical presentation
during an acute coronary syndrome (12,13). Angina is often
absent in patients with both end-stage renal disease
(ESRD) and coronary artery disease, occurring in only 17%
in one study (14). The electrocardiogram can be equally
unreliable, as ST-segment changes are difficult to interpret
secondary to left ventricular hypertrophy, electrolyte distur-
bances, conduction abnormalities and medications.
In this paper, we discuss the frequency of cardiac tropo-
nin elevations in patients with renal dysfunction, with
attention to assay technology and the discordance in the
frequency of elevations between cardiac troponin I (TnI)
and cardiac troponin T (TnT). In addition, we review the
pathophysiology of troponin release, its modification and
clearance from the circulation, and possible explanations for
troponin elevations in patients with renal insufficiency.
Finally, we summarize available evidence pertaining to
prognosis and risk stratification using cardiac troponins in
renal failure, and make a practical suggestion on how to
better interpret elevated serum cardiac troponin levels in
patients with impaired renal function and suspected acute
coronary syndrome (ACS).
CARDIAC TROPONIN T AND TROPONIN I
ELEVATIONS IN RENAL INSUFFICIENCY:
PREVALENCE AND CHARACTERISTICS
Troponin biology and assay technology. Three troponin
proteins are present in both cardiac and skeletal muscle.
Cardiac troponin C is identical to the troponin C expressed
in skeletal muscle. However, cardiac TnT and TnI are each
derived from genes that are specific to the heart (15).
Monoclonal antibody assays can detect cardiac-specific TnT
and TnI (16). The original first generation TnT assay
consisted of a capture and detection antibody which bound
TnT in the sample, forming a sandwich complex. Recog-
nition of TnT requires that each of the two antibodies
recognize the same protein in the sample. The capture
antibody was cardiac specific, but the detection antibody
cross-reacted with skeletal muscle TnT (17). In 1997, a
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second-generation assay using cardiac specific capture and
detection antibodies was introduced with no cross-reaction
with skeletal TnT (18). Data derived from first-generation
cardiac TnT assays used after this date are no longer considered
“the gold standard” for laboratory testing. A newer third-
generation assay with similar specificity is now available using
the same cardiac-specific antibodies and substituting recombi-
nant human cardiac TnT as the material standard (19).
Frequency of cardiac TnT and TnI elevations. Studies
using the original first generation troponin assays on small
groups of patients with ESRD without clinical or electro-
cardiographic evidence of acute ischemia report up to 71%
of patients having increased TnT (3,20–22). Troponin I is
increased in only about 7% of patients with renal failure
(3,20,22,23). In two of these studies the number of TnT-
positive patients declined significantly when a more cardiac
specific, second generation TnT assay was used (71% to
17% and 54% to 15%) (3,22). However, second generation
TnT assays continue to demonstrate increased TnT in up to
53% of patients with renal failure and no clinical evidence of
acute myocardial necrosis (3,22,24–31).
Discordance between cardiac TnT and TnI elevations. Us-
ing the most current assays, cardiac TnT is elevated more
frequently than cardiac TnI in patients with renal failure.
The lower incidence of TnI elevations and the lack of
expression of cardiac TnI in non-cardiac tissue (3,32,33) has
prompted some to suggest that TnI may be a more specific
diagnostic and prognostic marker of ischemic heart disease
in patients with renal failure (34–36). However, this is not
the case in patients without renal failure, where two meta-
analyses (37,38) have shown similar ability of TnI and TnT
to predict adverse events.
Several important differences in cellular biology, protein
chemistry and assay technology between the two troponins
make it difficult to conclude that TnI is more cardiac specific
than TnT in the setting of renal failure. Approximately 7%
and 3.5% of cardiac TnT and TnI exist freely in the cardiac
myocyte cytoplasm, respectively (39). The rest is bound
within the sarcomere. This cellular distribution determines
release kinetics (40), with free cytosolic proteins being released
earlier. The TnT content per gram of myocardium is roughly
twice that of TnI (41). Additionally, TnI assays may have more
imprecision at the lower end of the reference range compared
to assays for TnT (24). It is unknown whether these differences
impart an advantage favoring TnT over TnI in the detection of
smaller amounts of myocardial necrosis.
Dialysis may differentially affect serum levels of TnT and
TnI. Regardless of the method of clearance or type of
membrane used, TnI levels decreased by up to 86% from pre
to post dialysis (24). However, mean TnT increased post
dialysis, and the percent of patients with elevated troponins
was higher post-dialysis, possibly due to hemoconcentra-
tion. Although the membranes used in their study should
only clear molecules with a maximal weight less than intact
TnT or TnI, the authors speculated that TnI, may adsorb
onto the dialysis membrane because of its hydrophobicity.
These findings have been confirmed by some groups
(42,43), but refuted by others (44).
Troponin T and TnI are released in different forms from
damaged myocytes after acute myocardial infarction (Fig. 1)
(45). Troponin T is released as intact TnT:I:C complex, free
TnT and smaller immunoreactive fragments. However, TnI
is only identified in intact TnT:I:C complex and TnI:C. As
a result of its hydrophobicity, free TnI may bind to other
Abbreviations and Acronyms
ACS  acute coronary syndrome
CK-MB  MB-fraction of creatine kinase
ESRD  end-stage renal disease
TnT  serum cardiac troponin T
TnI  serum cardiac troponin I
Figure 1. Troponin release profile after myocardial infarction. kDa  molecular weight in kiloDaltons; TnC  cardiac troponin C; TnI  troponin I; Tn
T:I:C  intact troponin complex; Tn I:C  binary troponin I:C complex; TnT  troponin T.
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surfaces and/or proteins, thus potentially masking its anti-
genic epitopes (46). Uremia augments the free serum
concentration and clearance of highly protein-bound drugs
such as fosphenytoin (47). It is unknown if uremia can alter
the detection, release or clearance of different troponin
subunits in the serum. This may be especially relevant for
protein bound cardiac TnI.
Once released into the circulation, TnI is susceptible to
various biochemical modifications including phosphoryla-
tion, oxidation and proteolysis (46,48,49). Proteolysis of
TnT has been described to a lesser extent (48). These
modifications affect the interaction of TnI with other
troponin molecules and alter recognition by monoclonal
antibodies, thus affecting assay performance (46,48,49).
Furthermore, pathological states such as ischemia and
myocardial stunning result in altered proteolytic profiles of
TnI (50). The specific effects of renal failure on TnI
chemistry are unknown and studies characterizing the bio-
chemical profile of troponin degradation products in these
patients may provide helpful information. Perhaps TnI is
more susceptible to chemical modification and less stable
than TnT in the circulation of patients with renal insuffi-
ciency.
ORIGIN OF CARDIAC TROPONIN ELEVATIONS
IN PATIENTS WITH RENAL INSUFFICIENCY
“Uremic skeletal myopathy”: A source of cardiac tropo-
nin T? Many investigators hypothesize that uremic-
induced skeletal myopathy may be responsible for increased
troponins in renal failure. The hypothesis centers on the
notion that uremia may promote re-expression of cardiac
TnT from injured or regenerating skeletal muscle fibers.
Indeed, the skeletal muscle from patients on maintenance
hemodialysis has significant morphological changes by both
electron and light microscopy (51). Early reports describe
elevated serum TnT levels in patients with skeletal muscle
injury or inflammatory myopathies in the absence of any
obvious history of myocardial ischemia (52,53). Serum levels
of cardiac TnT are also increased at the end of a marathon
in male runners without known coronary artery disease (54).
These reports used first generation TnT assays that have
known cross-reactivity to skeletal TnT.
Several isoforms of cardiac TnT have been described in
developing and adult myocardial tissues (16,55,56). A TnT
species closely resembling cardiac TnT isoforms has been
found in human fetal skeletal muscle (57) and in skeletal
muscle of other developing animals (56). These cardiac-like
TnT isoforms decrease during maturation, resulting in their
absence in non-diseased adult human and rat skeletal
muscle (16,32,56,57). On the contrary, neither cardiac TnI
nor any of its isoforms have been demonstrated in skeletal
muscle (3,32,33).
Could the metabolic perturbations of renal failure stim-
ulate re-expression of cardiac TnT isoforms in skeletal
muscle? Perhaps more importantly, if re-expression of
cardiac TnT isoforms takes place in skeletal muscle, can
these isoforms be detected in the serum of patients with
renal failure by the current TnT serum assays? Using
polymerase chain reaction or western blot techniques, some
groups have identified cardiac-like TnT isoforms and mes-
senger ribonucleic acid in skeletal muscle from patients with
ESRD (3,16,18,32). However, the monoclonal antibodies
in the second-generation TnT would not detect the cardiac
TnT isoforms in these samples (16,32) or in skeletal muscle
biopsies from Duchenne muscular dystrophy patients with
increased serum cardiac TnT and no clinical or echocardio-
graphic evidence of cardiac disease (58). There is no close
association between increased serum cardiac TnT and clin-
ical or electromyographic changes of skeletal myopathy in
patients with ESRD (59). In summary, there are insufficient
data to support a skeletal muscle source for serum cardiac
TnT elevations in patients with ESRD.
Other potential contributions to serum troponin eleva-
tions. Serum troponin elevation may be the result of small
areas of clinically silent myocardial necrosis. Pathological
evidence exists documenting the presence of such micro-
infarctions in patients with elevated troponins (60,61).
These infarctions may be unrecognized clinically and may
not be associated with increased serum CK-MB. It is
possible that patients with ESRD are more likely to sustain
repeated episodes of clinically silent micro-infarctions sec-
ondary to their high incidence of coronary artery disease.
There are data indicating that serum TnT and TnI are
increased in patients with heart failure in the absence of
acute ischemia (62,63). Such troponin elevations associate
with prognosis and severity of heart failure (62), although a
recent study has demonstrated that only serum elevations of
cardiac TnT but not TnI were predictive of all cause and
cardiovascular mortality in patients with dialysis-dependent
renal failure (64). Patients with renal failure have a high
incidence and prevalence of heart failure, and epidemiolog-
ical data suggest that the prevalence of heart failure increases
during the transition from mild renal insufficiency to ESRD
(65). There is a possibility that apoptosis might explain
modest elevation of serum troponin, but this concept has
been understudied. If increased serum troponins in patients
with decreased renal function indicate myocardial damage,
could these markers identify patients at risk to develop heart
failure? Such patients might benefit from further testing
with echocardiography. In one small study, all patients with
chronic renal failure, elevated antemortem cardiac TnT and
no clinical evidence of acute myocardial infarction, had
cardiac pathology consisting of either recent acute myocar-
dial infarction/microinfarct, healing microinfarct, heart fail-
ure/degenerative changes or other myocardial pathology
(60).
Patients with renal failure frequently have left ventricular
hypertrophy. The presence of left ventricular hypertrophy is
significantly correlated with increased TnT in patients with
ESRD without acute myocardial ischemia (66). The relative
amount of individual troponin isoforms changes in hyper-
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trophied myocardium (67). It is possible that failing or
hypertrophied hearts have a different mechanism of release
of troponin into the serum, reflecting overall changes in
myocardial protein turnover (68).
It is unlikely that elevated serum troponin is the result of
decreased clearance by the failing kidney. Free TnT and
bound TnT are relatively large molecules (37 and 77 kDa,
respectively), similar in molecular weight to albumin (60
kDa), making it improbable that the kidney would be
responsible for their clearance. Creatine kinase and its
isoforms are of similar size and are mainly cleared by the
reticulo-endothelial system (69), whereas myoglobin is
smaller (18 kDa) and cleared by the kidney (70). It is
possible that smaller immunoreactive troponin fragments
are cleared by the kidney, but this remains to be clarified.
Improvement in renal function after renal transplant does
not appear to alter the occurrence of elevated serum tropo-
nin (71). Even if the kidney were partially responsible for
troponin clearance, it does not explain why troponin is released
from the heart. Furthermore, the majority of studies have failed
to show a relationship between serum creatinine concentra-
tions and overall frequency or degree of troponin elevation
(3,6,44,72). During myocardial necrosis the elimination rate
and apparent half-life of serum cardiac TnI is not significantly
different in patients with normal renal function or ESRD (73).
Additionally, preliminary results from western blot analysis fail
to implicate renal tissue as the source of serum cardiac TnT in
patients with renal failure (74).
CARDIAC TROPONIN ELEVATION IN
RENAL INSUFFICIENCY: WHAT DOES IT MEAN?
Reports of positive serum troponin in patients with renal
failure have relied upon historical, clinical, electrocardio-
graphic and rarely, echocardiographic data to exclude isch-
emic myocardial injury. Other studies have incorporated
traditional markers such as CK-MB as the diagnostic
benchmark to “diagnose” acute myocardial infarction. The
resting electrocardiogram and risk factors taken from the
medical history are neither sensitive nor specific in diagnos-
ing acute myocardial ischemia (75). Furthermore, the use of
traditional cardiac markers as the diagnostic standard for
acute ischemic injury assumes that troponins have an infe-
rior or equal sensitivity.
The decreased sensitivity of functional stress testing in
patients with ESRD (76) and the lack of information on
plaque morphology provided by angiography, may leave us
without a true laboratory or radiological gold standard to
diagnose myocardial ischemia/infarction. Rather, we may
have to rely on cardiovascular and overall clinical outcomes
to determine if troponin elevations in patients with renal
failure are reflective of cardiovascular disease and/or in-
creased risk of death.
Patients with renal insufficiency and no suspicion for
myocardial ischemia. Multiple studies have been pub-
lished regarding the prognostic power of serum troponin in
the setting of renal insufficiency (24–27,31,35,44,72). Re-
cently, several studies using second-generation cardiac tro-
ponin assays in larger populations studied over a longer
period of time have been published. A significant difference
in overall one year survival was noted for patients with
ESRD and serum TnT  0.1 ng/ml by laboratory and
bedside second-generation assays (28). Another group stud-
ied 102 patients with ESRD without any clinical evidence
of acute ischemic heart disease (29). Troponin T  0.1
ng/ml was strongly associated with all cause mortality and
TnT  0.05 ng/ml was associated with fatal cardiovascular
disease events. This association was independent of baseline
presence of heart disease. All patients with non-detectable
TnT were alive at follow up. The largest population studied
to date was recently published, consisting of 244 patients on
chronic hemodialysis for up to 34 months (30). Troponin T
was significantly associated with death from all causes, with
the strongest association for TnT values above the clinical
event threshold of 0.1 ng/ml. A trend of increasing TnT
measurements during longitudinal follow up was also pre-
dictive of progression of cardiac disease and all-cause
mortality. Taken together, the three largest prospective
studies of patients with renal failure strongly suggest an
association between troponin elevation and risk of death.
We believe that TnT may prove to be a marker of
subclinical myocyte damage in patients with renal failure.
This may be secondary to clinically silent myocardial necro-
sis or perhaps, unrecognized heart failure.
Patients with renal insufficiency and suspected acute
coronary syndrome. In the setting of suspected ACS and
renal failure, the interpretation of serum troponin is prob-
lematic. Martin studied 56 patients with renal failure
suspected of having acute myocardial ischemia (34). Pa-
tients with elevated TnI subsequently underwent echocar-
diography, nuclear stress testing or angiography. Each
patient had a study positive for myocardial ischemia. Tro-
ponin I was more sensitive (94% vs. 44%) and specific
(100% vs. 56%) than CK-MB for predicting myocardial
ischemia. This was subsequently confirmed in another study
(36). A recent report showed that elevated TnT or TnI was
less predictive of adverse outcomes (in hospital and at six
months) in patients with suspected ACS and renal failure
(72). The authors suggested using a higher threshold for
TnT (0.5 g/l) to optimize accuracy in predicting adverse
outcomes. No significant difference in predictive value was
found comparing the two troponins directly. However, a
recent analysis of 7,033 patients from the Global Use
of Strategies To Open occluded coronary arteries
(GUSTO)-IV ACS trial found that the prognostic value of
cardiac TnT was not diminished in patients presenting with
renal insufficiency and suspected ACS (77). In fact, patients
who presented with positive TnT and concomitant renal
insufficiency had the highest overall risk of death or acute
myocardial infarction. In a retrospective analysis comparing
with standard biomarkers such as myoglobin or CK-MB,
cardiac TnI was also found to be the most consistent marker
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across the spectrum of patients with renal dysfunction
(including dialysis-dependent patients) in the setting of
acute evaluation for suspected myocardial infarction (78).
From a practical standpoint, sequential serum troponin
levels should be measured in patients with renal failure and
suspected ACS. A sequential rise in serum troponin is
consistent with new myocardial damage in patients with
renal insufficiency. This can be measured in multiple time-
points during the early hours of presentation. An elevated
but invariant troponin level may be more consistent with no
new myocardial injury. The clinical status of the patient
must also guide the clinician in interpreting the significance
of troponin elevations in patients with renal failure and
suspected ACS.
Treatment of patients with renal insufficiency and ele-
vated serum troponins. There are no specific guidelines
regarding therapy for patients with renal insufficiency,
suspected ACS and elevated serum troponins. All patients
with ACS and renal insufficiency should be risk stratified
according to their clinical stability, serum markers and
12-lead electrocardiogram. It is reasonable to administer
antiplatelet therapy, beta-blockers, oxygen and nitroglyc-
erin. The use of antithrombin inhibitors and glycoprotein
IIb/IIIa antagonists is unclear at this time, since patients
with renal insufficiency have been excluded from most
clinical trials. Recent data have shown effectiveness and
safety of tirofiban in patients with mild to moderate renal
insufficiency (79). The decision to use early coronary an-
giography must be individualized.
Patients with clinically stable ESRD and elevated serum
TnT should be treated with aggressive risk factor modifi-
cation (HMG-CoA reductase inhibitors, aspirin, and anti-
hypertensive therapy). If echocardiography reveals LV dys-
function, appropriate therapies should be instituted at doses
commensurate with renal function. Coronary angiography is
the gold standard for establishing the diagnosis of coronary
disease and should be considered, especially in patients
being evaluated for renal transplantation. The decision to
use percutaneous and surgical revascularization in this pa-
tient population is complex, as these patients generally have
more severe coronary lesions, higher rates of re-stenosis and
higher peri-procedure morbidity and mortality (80).
Conclusions. Measurement of serum cardiac troponin has
revolutionized the management of ACS. It is a reliable
biomarker, useful to guide therapy and to predict outcomes.
However, increased serum cardiac troponin levels are fre-
quently observed in patients with renal insufficiency even
when the suspicion of active ischemia is relatively low.
Although the underlying pathophysiology of this abnormal-
ity is still not clearly understood, it may reflect ongoing,
often subclinical, myocardial damage (or micro-infarctions)
that is partially independent of acute ischemic injury.
Whatever the mechanisms involved, sequential serum car-
diac TnT or TnI elevation is indicative of acute myocardial
damage and denotes increased risk of morbidity and mor-
tality in patients with renal insufficiency regardless of the
presence of symptoms. In contrast, the negative predictive
value of troponins is still highly useful in this population.
Further studies are necessary to determine the disease
mechanism behind persistently elevated serum troponin
levels in asymptomatic patients with chronic renal failure.
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